To CRISPR or Not to CRISPR, That Is the Question: IP, Technical Issues & the 3Rs

Webinar Overview

The use of CRISPR/Cas9* genome editing for the creation of unique rodent models of human disease has revolutionized the field - but every revolution raises challenging issues.

View our presentation as we review the latest considerations for the technology as it applies to in vivo research and answer key questions including:

  • CRISPR/Cas9 IP/license constraints: how does it impact your project?
  • Is it compatible with the goals of the 3Rs?
  • Does CRISPR allow for the generation of relevant models?

Presenter

  • Jean Cozzi, PhD, Innovation Manager, Charles River

 

*CRISPR/CAS9 used under licenses to granted and pending US and international patents from The Broad Institute and ERS Genomics Limited.